Mechanisms of tumor-promoting activities of nicotine in lung cancer: synergistic effects of cell membrane and mitochondrial nicotinic acetylcholine receptors by Alex I Chernyavsky et al.
Chernyavsky et al. BMC Cancer  (2015) 15:152 
DOI 10.1186/s12885-015-1158-4RESEARCH ARTICLE Open AccessMechanisms of tumor-promoting activities of
nicotine in lung cancer: synergistic effects of cell
membrane and mitochondrial nicotinic
acetylcholine receptors
Alex I Chernyavsky1, Igor B Shchepotin2, Valentin Galitovkiy1 and Sergei A Grando1,3,4*Abstract
Background: One of the major controversies of contemporary medicine is created by an increased consumption of
nicotine and growing evidence of its connection to cancer, which urges elucidation of the molecular mechanisms
of oncogenic effects of inhaled nicotine. Current research indicates that nicotinergic regulation of cell survival and
death is more complex than originally thought, because it involves signals emanating from both cell membrane
(cm)- and mitochondrial (mt)-nicotinic acetylcholine receptors (nAChRs). In this study, we elaborated on the novel
concept linking cm-nAChRs to growth promotion of lung cancer cells through cooperation with the growth factor
signaling, and mt-nAChRs— to inhibition of intrinsic apoptosis through prevention of opening of mitochondrial
permeability transition pore (mPTP).
Methods: Experiments were performed with normal human lobar bronchial epithelial cells, the lung squamous cell
carcinoma line SW900, and intact and NNK-transformed immortalized human bronchial cell line BEP2D.
Results: We demonstrated that the growth-promoting effect of nicotine mediated by activation of α7 cm-nAChR
synergizes mainly with that of epidermal growth factor (EGF), α3— vascular endothelial growth factor (VEGF), α4—
insulin-like growth factor I (IGF-I) and VEGF, whereas α9 with EGF, IGF-I and VEGF. We also established the
ligand-binding abilities of mt-nAChRs and demonstrated that quantity of the mt-nAChRs coupled to inhibition of mPTP
opening increases upon malignant transformation.
Conclusions: These results indicated that the biological sum of simultaneous activation of cm- and mt-nAChRs produces
a combination of growth-promoting and anti-apoptotic signals that implement the tumor-promoting action of
nicotine on lung cells. Therefore, nAChRs may be a promising molecular target to arrest lung cancer progression
and re-open mitochondrial apoptotic pathways.
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One of the major controversies of contemporary medi-
cine is created by an increased consumption of nicotine
and growing evidence of its connection to cancer
(reviewed in [1]). Nicotine can contribute in a variety of
ways to cancer survival, growth, metastasis, resistance to
chemotherapy, and create a tumor-supporting micro-
environment, thus implementing a "second hit" that ag-
gravates aberrant signaling and elicits survival and
expansion of cells with genomic damage [1]. The list of
cancers reportedly connected to nicotine is expanding,
and presently includes small- and non-small cell lung
carcinomas as well as head and neck, gastric, pancreatic,
gallbladder, liver, colon, breast, cervical, urinary bladder
and kidney cancers ([1] and references therein).
Once limited to cigarettes, cigars, pipe tobacco and
chewing or spit tobacco, nicotine-containing products
today come in more flavors, forms, shapes and sizes, and
with more unproven health claims. Electronic cigarettes
(eCigs) that aerosolize nicotine without generating toxic
tobacco combustion products are rapidly gaining accept-
ance as an alternative to conventional cigarettes with
little knowledge regarding their biomedical effects [2-4].
eCig use, or vaping, allows to achieve systemic nicotine
concentration similar to that produced from traditional
cigarettes [5]. Although eCigs are generally recognized
as a safer alternative to combusted tobacco products,
there are conflicting claims about the degree to which
these products warrant concern for the health of the
vapers [6,7], and there is a risk of a second- and third-
hand exposure to nicotine from eCigs [8]. Thus, there
is an urgent need for elucidation of the molecular
mechanism of oncogenic effects of inhaled nicotine to
facilitate development and evaluation of safety mea-
sures for eCigs.
Nicotine can displace the autocrine and paracrine
hormone-like molecule acetylcholine (ACh) from the
nicotinic class of ACh receptors (nAChRs) expressed in
lung cells due to its higher receptor-binding affinity.
ACh is produced practically by all types of human cells,
and is remarkably abundant in the lung epithelium
[9,10]. Increasingly, a wider role for ACh in cell biology
is being recognized, including proliferation, differenti-
ation, apoptosis, adhesion and motility (reviewed in
[11,12]). The final cellular response to ACh is deter-
mined by the delicate balance between the growth-
promoting and inhibiting signals. The extracellular pool
of ACh is replenished by vesicular ACh transporter
secreting the ACh-containing vesicles, whereas the intra-
cellular pool is represented mainly by free cytoplasmic
ACh [13,14]. In human bronchioalveolar carcinoma
cells, nicotine upregulates choline acetyltransferase and
vesicular ACh transporter, thus increasing production
and secretion of ACh [15]. Nicotine also can upregulatenAChR expression [16], thus shifting ACh signaling in
lung cells toward the nicotinic vs. muscarinic physio-
logical signaling pathways.
The nAChRs are classic representatives of superfamily
of the ligand-gated ion channel pentameric receptor
proteins composed of ACh binding α subunits and
"structural" subunits. Lung cells can express the α1, α2,
α3, α4, α5, α6, α7, α9, α10, β1, β3, β2, β4, γ, δ and ε
nAChR subunits [17-22]. The differences in subunit
composition determine the functional and pharmaco-
logical characteristics of the receptor pentamers formed,
so that the net biological effect produced by a nicotinic
agonist depends on the subtype of nAChR binding this
ligand with the highest affinity. While direct involvement
of α7 nAChR has been documented in the pathophysi-
ology of lung cancer [23], α9 nAChR is known to play
an important role in breast cancer [24-26]. Silencing of
the expression of nAChR subunits and treatment with
nAChR antagonists produce anti-tumor effects both
in vitro and in vivo [15,25,27-32].
The nAChR subunit proteins can physically associate
with both protein kinases and protein tyrosine phospha-
tases in large multimeric complexes [33]. Even a short-
term exposure to nicotine activates mitogenic signaling
pathways involving signaling kinases [34]. The nAChRs
mediate the nicotine-dependent upregulation of genes
contributing to progression of lung cancer [35-38].
Current research, however, indicates that nicotinergic
regulation of cell survival and death is more complex than
originally thought. The emerging picture is that a diver-
sity of molecular signaling circuitries regulating cancer
cell growth signifies cross-talk interactions between cell
membrane (cm-)nAChRs and growth factor (GF)
receptors (GFRs), and receptors to various other auto-
crine and paracrine mediators [1]. Additionally, modu-
lation of functional electron transport in mitochondria
has been recently found to play an important role in
implementing the nicotine action interfering with
chemotherapy-induced apoptosis [39].
Nicotine can permeate lung cells and activate the
mitochondrial (mt-)nAChR subtypes found on the
mitochondrial outer membrane of lung cells [40]. Acti-
vation of these receptors may inhibit opening of mPTP,
which can block the initial step of intrinsic apoptosis
[41-44]. The mPTP is a multi-component protein ag-
gregate comprised by structural elements of the inner
as well as outer mitochondrial membrane that form a
non-specific pore permeant to any molecule of
<1.5 kDa in the outer mitochondrial membrane under
conditions of elevated matrix Ca2+. mPTP opening
causes massive swelling of mitochondria, rupture of
outer membrane and release of intermembrane compo-
nents that induce intrinsic apoptosis, such as cyto-
chrome c (CytC). Mitochondria become depolarised
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stimulation of ATP hydrolysis [45-47].
We hypothesized that the tumor-promoting activities
of nicotine are implemented through two principally dif-
ferent mechanisms — facilitation of growth of cancer
cells and prevention of their death, which results primar-
ily from a synergistic proliferative action of cm-nAChRs
with their partnering GFRs and activation of the mt-
nAChRs coupled to inhibition of mPTP opening, re-
spectively. To pin down the principal mechanisms
through which nicotine contributes to lung cancer, we
focused our studies of cm-nAChRs on regulation of lung
cancer growth and proliferation and studies of mt-
nAChRs — on cell protection from intrinsic apoptosis.
We found that the growth-promoting effect of nicotine
mediated by activation of α7 cm-nAChR synergizes
mainly with that of epidermal GF (EGF), α3 — vascular
endothelial GF (VEGF), α4 — insulin-like GF I (IGF-I)
and VEGF and α9 — EGF, IGF-I and VEGF. We also
established the ligand-binding abilities of mt-nAChRs
and demonstrated that quantity of the mt-nAChRs
coupled to inhibition of mPTP opening increases upon
malignant transformation of lung cells. These results
indicated that the biological sum of effects resulting
from simultaneous activation of nAChRs on the cell
membrane and mitochondria produces a combination
of growth-promoting and anti-apoptotic signals that




Normal human lobar bronchial epithelial cells (BEC) were
purchased from Life Technologies (Grand Island, NY) and
the established tumorigenic line of grade IV lung squa-
mous cell carcinoma SW900 — from American Type
Culture Collection (Catalog # HTB-59; Manassas, VA).
BEP2D cells — an established clonal population of HPV-
18-immortalized human BEC— was a gift from Dr. Harris
(NCI, NIH). For transformation, BEP2D cells were
incubated for 48 h with 2 μg/ml of 4-(methylnitrosa-
mino)-1-(3-pyridyl)-1-butanone (NNK; Toronto Research
Chemicals, North York, ON, Canada) and then grown for
5 passages, which was sufficient to induce malignant
transformation evidenced by anchorage-independent
growth and tumor formation in Nu/Nu mice [48]. All
types of lung cells were grown in the Cambrex bronchial
cell medium without retinoic acid and used in experi-
ments at ~80% confluence. The effects of test agents on
proliferation were evaluated by directly measuring the
number of viable, ie, trypan blue dye (TBD)-negative, cells
using a hemocytometer. The nAChR agonist nicotine, as
well as α-bungarotoxin (αBtx) — the specific inhibitor of
the "central" subtype of the neuronal nAChRs, such as α7[49], Mecamylamine (Mec)— a preferential blocker of the
"ganglionic" nAChR subtypes, such as α3- and α4-made
nAChRs [50], the metabolic inhibitor of ACh synthesis
hemicholinium-3 (HC-3), which inhibits ACh synthesis by
blocking cellular reuptake of its metabolic precursor cho-
line [51], staurosporine, heat-inactivated newborn calf
serum and all secondary antibodies were purchased from
Sigma-Aldrich Corporation, Inc. (St. Louis, MO). Human
recombinant EGF was obtained from R&D Systems, Inc.
(Minneapolis, MN), IGF-I — from GenWay Biotech Inc.
(San Diego, CA), and VEGF — from Abcam (Cambridge,
MA). The human cytochrome c (CytC) immunoassay was
purchased from R&D Systems and performed following
the protocol provided by the manufacturer. The nicotinic
radioligands (—)[N-methyl-3H]nicotine (specific activity
80.4 Ci/mmol), [3H]αBtx (specific activity 73.0 Ci/mmol)
and [3H]epibatidine (specific activity 54.0 Ci/mmol) were
purchased from GE Healthcare Bio-Sciences (Pittsburgh,
PA). The antibodies to human α3, α4, α7, and α9 nAChR
subunits were raised and characterized in our previous
studies [52-54]. The predesigned and tested small hairpin
(sh)RNAs targeting human CHRNA3, CHRNA4, CHRNA7
or CHRNA9, and scrambled shRNA were from OriGene
Technologies (Rockville, MD).
shRNA transfection experiments
For transfection of SW900 cells with the HuSH-29™ pre-
designed shRNA plasmids specific for human α3, α4, α7
and α9 nAChR subunits, we followed the standard
protocol described by us in detail elsewhere [55]. Briefly,
SW900 cells were seeded at a density of 1 × 104 cells per
well and exposed to experimental, ie, nAChR subunit
gene-specific shRNA, or negative control shRNA
(shRNA-NC) plasmids in GIBCO™ Opti-MEM I
Reduced-Serum Medium (Invitrogen, Carlsbad, CA)
with the TransIT®-Keratinocyte Transfection Reagent
(Mirus Bio LLC, Madison, WI). The transfection was
continued for additional periods of time to determine
changes of the relative protein levels of each targeted
nAChR subunit by immunoblotting and immunofluor-
escence. The maximum inhibition was achieved at 72 h
after transfection (data not shown), at which point the
shRNA-transfected cells were washed and exposed to
test nicotine/GF combinations for 24 h. At the end of
incubation, alive, ie, TBD-negative, cells were counted
with a hemocytometer.
Radioligand binding assays of mitochondrial proteins of
test lung cells
The mitochondrial protein fractions were purified from
large quantities of lung cell types used in this study
grown in the 225 cm2 T-flasks employing the mitochon-
drial/cytosol fractionation kit from BioVision Research
Products (Mountain View, CA), as described by us
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trypsinization, isolated by centrifugation, washed in PBS,
resuspended in the Cytosol Extraction Buffer containing
a mix of DTT and protease inhibitors, homogenized in
an ice-cold tissue grinderm and centrifuged at 700 × g
for 10 min at 4°C. The supernatant was re-centrifuged
at 10,000 × g for 30 min at 4°C, and the pelleted mito-
chondrial fraction was resuspended in 100 μl of the
Mitochondrial Extraction Buffer and used in the
radioligand-binding assays following the standard
protocol detailed by us elsewhere [57]. Depending on
the experimental conditions (see Results), the mitochon-
dria were exposed to either increasing concentrations
of the pan-nAChR radioligand nicotine or the saturat-
ing concentrations of the preferential radioligands of
the central and ganglionic nAChR subtypes, αBtx and
epibatidine, respectively [58,59]. After incubation, the
mitochondria were washed and solubilized with 1% SDS,
the protein concentration determined by a Bradford
protein assay kit (Bio-Rad Hercules, CA), and the radio-
activity counted in a liquid scintillation counter. The
specific binding was calculated by subtracting the non-
specific binding from total binding.
Sandwich (s)ELISA experiments
sELISA was performed as described elsewhere [60].
Briefly, ELISA plates were coated with either α3- or
α7-specific rabbit antibody or non-immune rabbit IgG
and blocked with 3% BSA. The lysates were applied into
the coated wells for 3 h at 37°C, after which the plates
were washed and incubated for additional 2 h with
biotinylated anti-α3 or anti-α7 antibody (both from
Antibodies-online, Inc., Atlanta, GA), followed by
ExtrAvidin-Peroxidase conjugate and o- phenylenedi-
amine dihydrochloride. The bound antibody was detected
at OD 490 nm using an ELISA plate reader.
Statistical analysis
All experiments were performed in triplicate or quadru-
plicate, and results expressed as mean ± SD. Statistical
significance was determined using Student's t-test. Dif-
ferences were deemed significant if the calculated p
value was <0.05.
Results
The cm-nAChRs regulate proliferation of normal and
malignant lung cells
Deprivation of cultured lung cells of auto/paracrine ACh
due to treatment with HC-3 almost completely inhibited
proliferation of all studied types of lung cells (Figure 1).
Nicotine sustained proliferation of HC-3-treated cells
(Figure 1). In a pilots study, we had determined that the
effect of nicotine was cell type- and dose-dependent,
with the dose of 3 μM completely restoring normalproliferation of BEC, 1 μM — intact BEP2D cells,
0.5 μM —NNK-transformed BEP2D cells and 1 μM —
SW900 cells.
The ability of nicotine to restore proliferation of the
HC-3-treated cells demonstrated critical role of the
nicotinergic arm of cholinergic regulatory axis in imple-
menting the growth-promoting activities of auto/para-
crine ACh on lung cells.
The growth-promoting effects of nicotine and GFs
synergize
Based on the knowledge on cooperation of nicotine with
GFs [1], we sought to obtain evidence that such binary
systems operate in lung cells. Toward this end, we
screened human GFs known to promote growth of lung
cancer cells, ie, EGF [61], IGF-I [62] and VEGF [63] util-
izing working concentrations of each GFs reported in
the literature, and the doses of nicotine restoring prolif-
eration of each type of lung cells under consideration
(Figure 1). Rather unexpectedly, we found that different
types of lung cells respond differently to combinations
of nicotine with different GFs. While the proliferation
rate significantly (p < 0.05) exceeding that established for
each stimulant given alone was produced by a combin-
ation of nicotine with EGF in all lung cell types, the
nicotine/IGF-I combination did so only in experiments
with NNK-transformed BEP2D and SW900 cells,
whereas the nicotine/VEGF combination — only in
SW900 cells (Figure 1). When the differences between
the elevated proliferation rate induced by a combination
of nicotine with a particular GF significantly (p < 0.05)
exceeded that induced by each stimulant given alone, we
attempted to abolish the additive effect by the antago-
nists or predominantly α7 and non-α7 nAChRs, αBtx
and Mec, respectively. Since these drugs do not pene-
trate the cell, they could inhibit cm-nAChRs, but not
mt-nAChRs. The additive effect of nicotine to the EGF-
induced proliferation could be abolished by αBtx,
whereas that to the IGF-I- or VEGF-induced prolifera-
tion — by Mec (Figure 1).
These results provided the first evidence that the
binary systems comprised by cm-nAChRs and GFRs
facilitate growth of lung cells. The differences in the effi-
cacies of different nicotine/GF combinations may be ex-
plained by the reputed differences in the cm-nAChR
repertoires and/or their downstream signaling pathways
among tested lung cell types.
Identification of the cm-nAChR subtypes implementing
synergy of nicotine with GFs
To elucidate the mechanisms of cooperation of cm-
nAChRs and GFRs, we focused on the cm-nAChR
subtypes that might implement the synergistic growth-
promoting effects of nicotine with EGF, IGF-I and VEGF
Figure 1 Synergistic effects of combinations of nicotine (N) with EGF (E), IGF-I (I) or VEGF (V) on proliferation of different types of lung
cells. Alive, ie, TBD-negative, cells seeded at a density of 1 × 104 per well of a 96-well plate were counted after 24 h of incubation in the absence
(intact control) or presence of the optimal doses of nicotine (see text) and 10 ng/ml of each test GF. Some cells were exposed to 20 μM HC-3
(H) ± nicotine and some— to nicotine/GF combinations in the presence of αBtx (B; 1 μM) and/or Mec (M; 50 μM). All values significantly (p < 0.05)
differed from the intact control, taken as 100%. Data are mean + SD from a triplicate sample. Asterisk = p < 0.05 compared to nicotine alone;
arrows = p < 0.05 between indicated conditions.
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synergistic effects of nicotine combinations with each
tested GFs (Figure 1). The involvement of a particular
cm-nAChR subtype in the binary interaction with GFRs
was determined based on disappearance of the additive
(synergistic) effect upon functional inactivation of the
cm-nAChR in question by transfection with anti-
receptor shRNAs, but not shRNA-NC. In keeping with
results obtained with pharmacological nAChR antago-
nists (Figure 1), silencing of the α7 gene selectively
inhibited synergy of nicotine with EGF (Figure 2). The
shRNA-α3 inhibited most effectively the nicotine syn-
ergy with VEGF, whereas shRNA-α4 — that with IGF-I
and VEGF equally efficiently. Interestingly, abolishing
signaling by α9 nAChRs significantly (p < 0.05) decreasedthe additive effect of nicotine to that of each tested GF
(Figure 2).
These results indicated that α7 cm-nAChR cooperates
mainly with the EGF, α3 — VEGF, α4 — IGF-I and
VEGF and α9 — EGF, IGF-I and VEGF receptors.
Differences of the ligand-binding parameters of mt-
nAChRs in normal and malignant lung cells
First, we investigated whether the nAChR subunits detected
on mitochondria of lung cells by sELISA [40] can form func-
tional ligand-binding receptors, and then compared the
ligand-binding parameters of mt-nAChRs in normal and
malignant lung cells. Analysis of specific binding to mito-
chondria isolated from BEC and SW900 cells identified
functional ligand-binding sites, and also demonstrated that
Figure 2 Roles of individual cm-nAChR subtypes in implementing synergy of nicotine with GFs. The SW900 cells transfected with either
shRNA-NC (control; taken as 100%) or anti-nAChR shRNA were incubated for 24 h in the absence (1) or presence of combinations of 0.1 μM
nicotine with 10 ng/ml of EGF (2), IGF-I (3) or VEGF (4), and then subjected to direct counting (TBD-negative cells only). Data are mean + SD from
a triplicate sample. Asterisk = p < 0.05 compared to the untreated cells transfected with respective anti-nAChR shRNA (1).
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nAChRs (Figure 3).
Thus, the nAChR subunit proteins expressed on the
mitochondrial membrane of lung cells form functional
receptors, whose number is upregulated in cancer cells.
The oncogenic transformation alters the repertoire of
mt-nAChRs in BEP2D cells
Since malignant transformation of lung cells is associated
with changes in the cm-nAChR repertoire (reviewed in
[1]), we hypothesized that the repertoire of mt-nAChRs
might also change. To identify possible shift in the
repertoire of mt-nAChR subtypes associated with
malignant transformation of lung cells, we analyzedFigure 3 Saturable binding of [3H] nicotine to mitochondria isolated
mean radioactivity of quadruplicate samples of purified mitochondria expo
the absence (total binding) or presence (non-specific binding) of 1 M of nomitochondria from intact vs. NNK-transformed BEP2D
cells using a combination of radioligand-binging assay and
sELISA. By the former technique, we determined specific
binding of the preferred radioligands of α7 and non-α7
nAChRs, [3H] αBtx and [3H] epibatidine, respectively. By
the latter technique, we quantitated relative amounts of
α7- and α3-made nAChRs employing our α7- and α3-
selective antibodies. The radioligand-binging assay dem-
onstrated that mitochondria from the NNK-transformed
BEP2D cells featured increased amounts of both α7 and
non-α7 receptors, as judged from a 4.3-fold increase
of the [3H] αBtx- and a 2.4-fold increase of the [3H]
epibatidine-binding sites, compared to control, non-
transformed BEP2D cells (Figure 4). By sELISA, thefrom cultured BEC (A) and SW900 cells (B). Each point represents a
sed to increasing concentrations of [3H] nicotine for 45 min at 0o C in
n-labeled nicotine, as described in Materials and Methods.
Figure 4 Relative amounts of α7 and non-α7 mt-nAChR subtypes
in BEP2D cells before and after malignant transformation. The
transformation was achieved due to 48 h exposure to 2 μg/ml NNK
followed by 5 passages, and confirmed in the in vitro and in vivo
tumorigenicity assays (see Methods). In radioligand-binding assay, the
numbers of α7 and non-α7 nAChRs were estimated by the
amounts of specific binding of [3H] αBtx and [3H] epibatidine,
respectively. Quadruplicate samples of mitochondria from control
(intact) and NNK-transformed BEP2D cells were incubated for
30 min at 0o C with saturating concentrations of the radioligands.
The specific binding was calculated by subtracting the non-specific
binding from total binding. In sELISA, the mitochondrial proteins
were probed with anti-α7 or anti-α3 antibodies, as detailed in
Methods. Results of both assays are expressed as fold of control,
taken as 1. Data are mean + SD. Asterisk = p < 0.05 compared to
respective controls.
Figure 5 Nicotinergic effects on CytC release from BEC
mitochondria. The mitochondria freshly isolated from BEC were
exposed to 1 μM staurosporine (control) and incubated in triplicate for
45 min at 30 ° C with 10 μM nicotine in the absence or presence of
αBtx (1 μM) and/or Mec (50 μM). The mitochondria were pelleted
and the CytC concentration was measured in the supernatants, as
described in Materials and Methods. Data are mean + SD. Asterisk =
p< 0.05 compared to treatment with staurosporine alone, taken as 100%.
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the NNK-transformed BEP2D cells increased by 3.5- and
1.4-fold, respectively (Figure 4).
Thus, we obtained direct evidence that malignant
transformation of lung cells is associated with an
increased expression of α7 mt-nAChR and, perhaps,
some other mt-nAChR subtypes that may be coupled to
inhibition of mPTP opening [40].
Identification of the lung mt-nAChR subtypes coupled to
inhibition of apoptosis
To obtain an insight into the roles of different mt-
nAChR subtypes in the inhibition of mPTP opening in
lung cells, we measured effects of nicotinic ligands on
the staurosporine-induced CytC release, which is known
to be associated with mPTP opening and activation of
the intrinsic apoptotic pathway [64]. In keeping with
published reports [40,41,65], we observed that nicotine
significantly (p < 0.05) inhibited staurosporine-inducedCytC release from naked mitochondria isolated from
BEC (Figure 5). The ability of nicotine to block CytC re-
lease was significantly (p < 0.05) and insignificantly (p >
0.05) diminished in the presence of αBtx and Mec, re-
spectively. The mixture of αBtx and Mec completely
abolished the anti-apoptotic effect of nicotine (Figure 5).
These results demonstrated that activation of lung mt-
nAChRs by nicotine inhibits apoptogen-induced mPTP
opening, and indicated that both α7 and non-α7 mt-
nAChR subtypes may be involved in the anti-apoptotic
action of nicotine.
Discussion
This study elaborated on the novel concept linking cm-
nAChRs to growth promotion of lung cancer cells through
modification of GF signaling, and mt-nAChRs— to inhib-
ition of apoptosis due to prevention of mPTP opening.
The obtained results provided new insights into the
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mal and malignant lung cells. We demonstrated for the
first time that the nAChR-mediated growth-promoting ef-
fects of nicotine synergize with those of EGF, IGF-I and
VEGF. The causative role of activation of cm-nAChRs in
the growth-promoting action of nicotine was illustrated by
the ability to abolish its effect using the cell membrane-
impermeable nAChR antagonists. Different cm-nAChR
subtypes implemented the synergistic action of nicotine
with GFs in different types of lung cells. Also for the first
time, we demonstrated that mt-nAChRs implement the
anti-apoptotic activity of nicotine that permeates lung
cells. Thus, it appears that the oncogenic action of nico-
tine harbors both the growth-promoting and anti-
apoptotic signals emanating from the cell membrane and
the mitochondrial membrane due to activation of cm-
nAChRs and mt-nAChRs, respectively.
Concerns about safety of nicotine-containing products
necessitates research of the molecular mechanisms of
nicotine action on the tissues prone to develop tobacco-
related malignancy, such as lungs. The additive onco-
genic effect of nicotine is best illustrated in the lung
cancer model in A/J mice, wherein nicotine increases
both the numbers and the size of tobacco nitrosamine-
initiated lung tumors, and decreases survival probability
[23,34,66]. Furthermore, while smoking is an independ-
ent predictive factor of chemoresistance of lung cancer
[67], silencing of nAChRs in the non-small-cell lung
carcinoma cell lines suppresses nicotine-dependent che-
moresistance [68]. Therefore, it is currently believed that
nAChRs may be a novel drug target for prevention and
treatment of cancers [69-73].
Although nAChR is an ion channel mediating influx of
Na+ and Ca2+ and efflux of K+, its activation by a ligand,
such as nicotine, elicits both ionic and non-ionic signal-
ing events regulating phosphorylation and dephosphory-
lation of target proteins. Altogether, the downstream
signaling from cm-nAChRs has been shown to activate
protein kinase C isoforms, Ca2+/calmodulin-dependent
protein-kinase II, Jak2, phosphatidylinositol-3-kinase,
JNK, phospholipase C, EGFR kinase, Rac, Rho, p38 and
p44/42 MAPK, as well as the Ras-Raf1-MEK-ERK path-
way [74-87]. Notably, stimulation of α7 cm-nAChR in
keratinocytes triggers two complementary pathways.
The Ras-Raf1-MEK1-ERK cascade culminates in up-
regulated expression of the gene encoding STAT3,
whereas recruitment and activation of the tyrosine kin-
ase JAK2 phosphorylates it. Thus, cm-nAChRs couple
several non-receptor kinases that can activate different
signaling cascades merging with GFR pathways, with
the signal flow ending at the level of specific transcrip-
tion factors. For instance, it is well-documented that
nicotine accelerates wound healing by synergizing with
and mimicking the effects of various GFs [88-90].Nicotine can also upregulate expression of fibroblast
growth factor (FGF)1, FGF1 receptor, FGF2 and VEGF
[38,83,91-95]. Accordingly, nAChR inhibition reduces
FGF2 and VEGF upregulation [73,96]. In turn, FGF2
and IGF-I alter the cm-nAChR expression level and
clustering [97,98], which can modify biological effects
of auto/paracrine ACh, and nicotine.
It has been well-documented that nAChRs can medi-
ate the nicotine-dependent upregulation of proliferative
and survival genes, thus contributing to the growth and
progression of lung cancer cells in vitro and in vivo
[35-37]. In the present study, we demonstrated that a
combination of nicotine with EGF, IFG-I or VEGF
increases lung cell proliferation above the levels estab-
lished for each stimulant given alone. Since nicotine can
exert its biological effects due to binding to the cm-
nAChRs functionally linked to GFRs (reviewed in [1]),
its tumor-promoting activities may, therefore, rely on
the synergy of the cm-nAChR- and GFR-coupled signal-
ing events. The homomeric α7 nAChRs, homo- and/or
heteromeric α9-containing nAChRs as well as the α3-
and α4-made nAChR subtypes, all appeared to be
involved in the binary circuitries with GFRs facilitating
lung cancer cell growth. Thus, it has become apparent
that activation of cm-nAChRs primarily triggers signal-
ing events accelerating tumor growth, whereas activation
of mt-nAChRs primarily protects tumor cells from apop-
tosis. Admittedly, such "assignment" is somewhat artifi-
cial, since cm-nAChRs can also inhibit apoptosis by
upregulating anti-apoptotic factors (eg, [99]).
Although nicotine can freely permeate epithelial cells
and elicit pathobiological effects via intracellular mecha-
nisms [100-104], up until recently the pro-survival activ-
ities of nicotine had been attributed exclusively to
activation of cm-nAChRs. However, It has been recently
demonstrated that nAChR subunits are also expressed
on the mitochondrial outer membrane [42,43]. The
nAChR-subunit antibodies visualized the α3, α4, α7,
β2 and β4 subunits forming in the mitochondria of
lung cells the nAChRs that non-covalently connect to
voltage-dependent anion channels and control CytC
release by inhibiting mPTP opening [40,41]. We have
chosen staurosporine as an apoptogen, because it in-
creases mitochondrial membrane potential and induces
mitochondrial swelling and CytC release, which can be
blocked by an inhibitor mPTP opening [64,105]. Dem-
onstration of the mt-nAChRs preventing mPTP opening
was in keeping with independent reports about both the
presence of nAChRs on mitochondria [106] and the
mitochondria-protecting effects of nicotine [107,108].
Changes of the mt-nAChR expression patterns associ-
ated with malignant transformation of lung cells may
play an important role in the biology of cancer cells. We
demonstrated that mitochondria of the malignant lung
Chernyavsky et al. BMC Cancer  (2015) 15:152 Page 9 of 12cells SW900 expressed more nAChRs than normal BEC,
which is in keeping with the notion that cancer progres-
sion is associated with overexpression of nAChRs
(reviewed in [69,71,109]). An increase of mt-nAChR
numbers may allow malignant cells to bind a higher than
normal amounts of auto/paracrine ACh or nicotine. In
the cytosol, nicotine can shift the dynamic equilibrium
of the physiological regulation of cell survival and death,
because it is insensitive to the regulatory action of intra-
cellular acetylcholinesterase that hydrolyzes ACh in the
cytoplasm [110] and thus exerts the physiological con-
trol of anti-apoptotic action of mt-nAChRs, similar to
the effect of cell membrane-anchored acetylcholinester-
ase hydrolyzing extracellular ACh.
It has been documented that a switch of the predom-
inant nAChR expression pattern occurs during malig-
nant transformation of the cells (reviewed in [70,71]),
indicating that the effects of auto/paracrine ACh on can-
cer cells might differ from its effects on non-malignant
cells, even if they are situated next to each other in the
same tissue. The same holds true for nicotine, which has
a higher nAChR-binding affinity than ACh. The cumula-
tive results of our radioligand-binding assay and sELISA
indicated that malignant transformation of lung cells
was associated with an upregulated expression of pre-
dominantly the α7 mt-nAChR subtype. Notably, the
degree of increase of mt-nAChRs detected by a radioli-
gand was higher than that detected by a corresponding
antibody. This can be explained by the fact that, in con-
trast to the nAChR subunit-selective antibody, each radi-
oligand can label more than one nAChR subtype. Since
the specificity of many antibodies against nAChRs was put
in doubt [111,112], we had verified specificity of our anti-
bodies in the α7 and α3 knockout mice (data not shown).
Conclusions
The results of our experiments showing cooperation
between the binary signaling networks of specific cm-
nAChRs and GFRs, on the one hand, and the data on
inhibition of mPTP opening by mt-nAChRs on the
other, indicate that the biological sum of simultaneous
activation of nAChRs on the cell membrane and the
mitochondrial membrane by nicotine produces com-
bined growth-promoting and anti-apoptotic effects.
Noteworthily, inhibition of nAChR expression has been
shown to attenuate nicotine- or tobacco nitrosamine-
induced cell proliferation in vitro and/or in vivo
(reviewed in [1,109]). Therefore, elucidation of this novel
mechanism of tumor promoting action of nicotine
should pinpoint the lung cm-nAChR and mt-nAChR
subtypes that may become a promising molecular target
to prevent, reverse, or retard lung cancer progression
by receptor inhibitors. Since nicotine can protect
cancer cells from apoptosis and elicit chemoresistance(reviewed in [1]), learning the pharmacology of nicoti-
nergic regulation of mPTP opening should allow to re-
open the mitochondrial apoptotic pathways, thus restoring
sensitivity of lung cancer to chemotherapy.
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